CMPS

Compass Pathways plc - ADR (CMPS) | Rumor.io

Compass Pathways

CMPS

Attention (50-day avg)0.02%

Attention rank (50-day avg)#332

Bullish sentiment (50-day avg)87%

Price to earnings ratio-4.3

Market capitalization1.8B

Earnings per share-3.79

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-287.9M

Social

What share of all stock conversation is about CMPS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% +0	0.02% +0	0.01% +0.01

Sep 29

An investor believes that Compass Pathways plc (CMPS) will be acquired for a higher price than Atai after approval, potentially in the range of $3.5-4 billion, with a 30% premium to the current share price.
The company's stock price has declined by about 15% over the past week, but some investors are optimistic about a potential recovery.
An investor notes that the stock is undervalued and overlooked, and that the market may not be able to price it correctly due to the complexity of the treatment and the paradigm shift it represents.

Generated by AI

Sentiment

Of the messages about CMPS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	70.27% -29.73	81.45% -13.19	90.4% +10.19	87.06% +5.99
Bearish	29.73% +29.73	18.55% +13.19	9.6% -10.19	12.94% -5.99

Bullish· Sep 10

The $ATAI cash payout is expected to significantly benefit COMPASS Pathways plc ($CMPS) and Drive Therapeutics ($DFTX), with a potential redistribution of funds to the rest of the sector.
COMPASS Pathways plc ($CMPS) is expected to break through resistance and reach higher prices, with some analysts predicting a fair value of $33-45 and potential for higher prices after FDA approval.
COMPASS Pathways plc ($CMPS) is expected to have a high valuation in the near to mid future, with some analysts predicting a market cap of $4.6-6.25 billion and potential for a buyout at a premium of 35%.

Bearish· Jul 16

COMPASS Pathways plc's ($CMPS) recent price drop may be due to funds hedging their positions or exiting due to the stock's high volatility.
The company's manipulated market and lack of transparency may have contributed to its poor performance, with some investors expecting a price of $50 or lower.
COMPASS Pathways plc's ($CMPS) current price action is likely synthetic, and the stock may be repricing due to high short interest and a possible head and shoulder pattern, potentially leading to a minimum $4 billion loss.

Generated by AI

Topics

Of the messages about CMPS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.47%	74.38%	57.21%
Technical Analysis	—	9.92%	18.37%	8.67%
Analysts	—	0%	6.24%	11.92%
Earnings	—	0%	0%	1.54%
Controversies	—	6.61%	1.02%	0.43%
Macro	—	0%	0%	20.23%

Analysts· Apr 1

Morgan Stanley initiated coverage on COMPASS Pathways (CMPS) with an Overweight rating and a $30 price target.
Analysts expect the price target to impact the stock's performance, potentially moving the analyst's ranking.
The news is seen as a possible reason for the stock's recent price increase, with some investors holding CMPS and others expressing bullish sentiment.

Announcements· Jul 16

Compass Pathways plc (CMPS) announced the publication of a post-hoc analysis of support methods used in a Phase 2 study of its synthetic psilocybin treatment for post-traumatic stress disorder (PTSD).
The analysis demonstrated the distinction of COMP360 trial monitoring and support from psychotherapy, strengthening the scientific and commercial foundation of the company's regulatory and launch strategy.
The post-hoc analysis is a strategically important paper that supports Compass's central thesis that COMP360 is a drug-centered treatment with structured monitoring, rather than psychotherapy-centered care.

Controversies· Aug 9

COMPASS Pathways plc (CMPS) is being sued by Terran Biosciences for alleged misappropriation of trade secrets related to psilocybin.
The lawsuit refers to a provisional patent filed by CMPS in 2019 for the co-administration of psilocybin and a 5-HT2A specific antagonist.
CMPS' intellectual property is considered valuable, and the lawsuit may impact the company's leverage in the psychedelics space.

Generated by AI

Community

Of the messages about CMPS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.75%	88.57%	79.93%	42.2%
Newcomers	16.25%	11.43%	20.07%	57.8%

Regulars· Sep 29

Potential approval for COMPASS Pathways plc (CMPS) may not lead to a significant price increase, as the stock's year-to-date gain and market expectations for approval may already be reflected in the current price.
Regular participants are optimistic about CMPS' potential, with some predicting a significant price increase after approval, while others are hopeful for a more substantial price movement, potentially reaching $30.
The stock's short-term price action is volatile, with some participants attributing the recent decline to the market's perception of approval as likely, while others see the current price as undervalued and overlooked, with potential for a paradigm shift in valuation.

Newcomers· Sep 18

Many new investors are optimistic about COMPASS Pathways plc's (CMPS) future, with some predicting a significant increase in stock price over the next year.
Some users are focused on the potential for COMPASS Pathways to become a major player in the pharmaceutical industry, citing the company's strong team and growing momentum.
There is also speculation about the timing of COMPASS Pathways' FDA approval and launch, with some users predicting that it could happen as early as six months from now.

Generated by AI

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling. Speaking at T

5d agoYahoo Finance

COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk

6d agoInvesting.com

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

7d agoYahoo Finance

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global

7d agoYahoo Finance

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027. Speaking

8d agoYahoo Finance

COMPASS Pathways at Deutsche Bank summit: launch nears for COMP360

12d agoInvesting.com

Also Discussed

Investors talking about CMPS also mention

#	Name	Attention
1	ATA Inc-ChinaATAI	0%new
2	Cybin Inc.CYBN	0.01%+0
3	Definium Therapeutics, Inc.MNMD	0%+0
4	GH Research PLCGHRS	0%0
5	AdvisorShares Psychedelics ETFPSIL	0.02%+0.01
6	GBNH - Greenbrook TMS Inc.	——
7	SEEL - Seelos Therapeutics, Inc.	——
8	Bright Minds Biosciences Inc.DRUG	0%new
9	Alto Neuroscience Inc.ANRO	0%new
10	Silo Pharma Inc.SILO	0%new

Compass Pathways plc - ADR

Healthcare
Medical Care Facilities

Compass Pathways plc - ADR is a clinical-stage biotechnology company focused on mental health care. Compass Pathways develops COMP360, a proprietary synthetic psilocybin therapy being studied for treatment-resistant depression and other psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa. The company’s work centers on evidence-based psychedelic medicine, combining drug development with psychotherapy-oriented treatment models. Based in London, Compass Pathways operates across the United Kingdom and the United States and serves as a specialist participant in the emerging mental health therapeutics market. Its current business is centered on advancing investigational treatments through clinical trials and preparing for broader medical use if approved.

Website

Location

33 Broadwick Street

London, W1F 0DQ

United Kingdom

Social

What share of all stock conversation is about CMPS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% +0.02	0.01% +0	0.02% +0	0.01% +0.01

Sep 29

An investor believes that Compass Pathways plc (CMPS) will be acquired for a higher price than Atai after approval, potentially in the range of $3.5-4 billion, with a 30% premium to the current share price.
The company's stock price has declined by about 15% over the past week, but some investors are optimistic about a potential recovery.
An investor notes that the stock is undervalued and overlooked, and that the market may not be able to price it correctly due to the complexity of the treatment and the paradigm shift it represents.

Generated by AI

Sentiment

Of the messages about CMPS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	70.27% -29.73	81.45% -13.19	90.4% +10.19	87.06% +5.99
Bearish	29.73% +29.73	18.55% +13.19	9.6% -10.19	12.94% -5.99

Bullish· Sep 10

The $ATAI cash payout is expected to significantly benefit COMPASS Pathways plc ($CMPS) and Drive Therapeutics ($DFTX), with a potential redistribution of funds to the rest of the sector.
COMPASS Pathways plc ($CMPS) is expected to break through resistance and reach higher prices, with some analysts predicting a fair value of $33-45 and potential for higher prices after FDA approval.
COMPASS Pathways plc ($CMPS) is expected to have a high valuation in the near to mid future, with some analysts predicting a market cap of $4.6-6.25 billion and potential for a buyout at a premium of 35%.

Bearish· Jul 16

COMPASS Pathways plc's ($CMPS) recent price drop may be due to funds hedging their positions or exiting due to the stock's high volatility.
The company's manipulated market and lack of transparency may have contributed to its poor performance, with some investors expecting a price of $50 or lower.
COMPASS Pathways plc's ($CMPS) current price action is likely synthetic, and the stock may be repricing due to high short interest and a possible head and shoulder pattern, potentially leading to a minimum $4 billion loss.

Generated by AI

Topics

Of the messages about CMPS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.47%	74.38%	57.21%
Technical Analysis	—	9.92%	18.37%	8.67%
Analysts	—	0%	6.24%	11.92%
Earnings	—	0%	0%	1.54%
Controversies	—	6.61%	1.02%	0.43%
Macro	—	0%	0%	20.23%

Analysts· Apr 1

Morgan Stanley initiated coverage on COMPASS Pathways (CMPS) with an Overweight rating and a $30 price target.
Analysts expect the price target to impact the stock's performance, potentially moving the analyst's ranking.
The news is seen as a possible reason for the stock's recent price increase, with some investors holding CMPS and others expressing bullish sentiment.

Announcements· Jul 16

Compass Pathways plc (CMPS) announced the publication of a post-hoc analysis of support methods used in a Phase 2 study of its synthetic psilocybin treatment for post-traumatic stress disorder (PTSD).
The analysis demonstrated the distinction of COMP360 trial monitoring and support from psychotherapy, strengthening the scientific and commercial foundation of the company's regulatory and launch strategy.
The post-hoc analysis is a strategically important paper that supports Compass's central thesis that COMP360 is a drug-centered treatment with structured monitoring, rather than psychotherapy-centered care.

Controversies· Aug 9

COMPASS Pathways plc (CMPS) is being sued by Terran Biosciences for alleged misappropriation of trade secrets related to psilocybin.
The lawsuit refers to a provisional patent filed by CMPS in 2019 for the co-administration of psilocybin and a 5-HT2A specific antagonist.
CMPS' intellectual property is considered valuable, and the lawsuit may impact the company's leverage in the psychedelics space.

Generated by AI

Community

Of the messages about CMPS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.75%	88.57%	79.93%	42.2%
Newcomers	16.25%	11.43%	20.07%	57.8%

Regulars· Sep 29

Potential approval for COMPASS Pathways plc (CMPS) may not lead to a significant price increase, as the stock's year-to-date gain and market expectations for approval may already be reflected in the current price.
Regular participants are optimistic about CMPS' potential, with some predicting a significant price increase after approval, while others are hopeful for a more substantial price movement, potentially reaching $30.
The stock's short-term price action is volatile, with some participants attributing the recent decline to the market's perception of approval as likely, while others see the current price as undervalued and overlooked, with potential for a paradigm shift in valuation.

Newcomers· Sep 18

Many new investors are optimistic about COMPASS Pathways plc's (CMPS) future, with some predicting a significant increase in stock price over the next year.
Some users are focused on the potential for COMPASS Pathways to become a major player in the pharmaceutical industry, citing the company's strong team and growing momentum.
There is also speculation about the timing of COMPASS Pathways' FDA approval and launch, with some users predicting that it could happen as early as six months from now.

Generated by AI

Compass Pathways

Social

Sep 29

Bullish· Sep 10

Bearish· Jul 16

Analysts· Apr 1

Announcements· Jul 16

Controversies· Aug 9

Regulars· Sep 29

Newcomers· Sep 18

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

COMPASS Pathways at Deutsche Bank summit: launch nears for COMP360

Also Discussed

Compass Pathways plc - ADR

Company Information

Location

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

COMPASS Pathways at Deutsche Bank summit: launch nears for COMP360

Also Discussed

Social

Sep 29

Bullish· Sep 10

Bearish· Jul 16

Analysts· Apr 1

Announcements· Jul 16

Controversies· Aug 9

Regulars· Sep 29

Newcomers· Sep 18